Reviva Pharmaceuticals Holdings Inc. (NASDAQ:RVPH) — Market Cap & Net Worth
Market Cap & Net Worth: Reviva Pharmaceuticals Holdings Inc. (RVPH)
Reviva Pharmaceuticals Holdings Inc. (NASDAQ:RVPH) has a market capitalization of $6.02 Million ($6.02 Million) as of August 3, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #28188 globally and #5722 in its home market, demonstrating a 4.42% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Reviva Pharmaceuticals Holdings Inc.'s stock price $0.47 by its total outstanding shares 12810377 (12.81 Million). Review how much free cash does Reviva Pharmaceuticals Holdings Inc. generate to assess how much free cash flow the company generates relative to operating cash flow.
Reviva Pharmaceuticals Holdings Inc. Market Cap History: 2018 to 2026
Reviva Pharmaceuticals Holdings Inc.'s market capitalization history from 2018 to 2026. Data shows change from $126.18 Million to $6.02 Million (-32.21% CAGR).
Index Memberships
Reviva Pharmaceuticals Holdings Inc. is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.46 Trillion | 0.00% | #818 of 976 |
|
NASDAQ Composite
IXIC
|
$40.26 Trillion | 0.00% | #2611 of 3165 |
Weight: Reviva Pharmaceuticals Holdings Inc.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Reviva Pharmaceuticals Holdings Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Reviva Pharmaceuticals Holdings Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of RVPH by Market Capitalization
Companies near Reviva Pharmaceuticals Holdings Inc. in the global market cap rankings as of August 3, 2026.
Key companies related to Reviva Pharmaceuticals Holdings Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #424 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #543 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #563 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $477.10 |
| #424 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $762.63 |
| #543 | Argen-X | BR:ARGX | $49.55 Billion | €745.00 |
| #563 | UCB SA | BR:UCB | $47.34 Billion | €222.90 |
Reviva Pharmaceuticals Holdings Inc. Historical Marketcap From 2018 to 2026
Between 2018 and today, Reviva Pharmaceuticals Holdings Inc.'s market cap moved from $126.18 Million to $ 6.02 Million, with a yearly change of -32.21%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $6.02 Million | +68.46% |
| 2025 | $3.57 Million | -84.59% |
| 2024 | $23.19 Million | -64.85% |
| 2023 | $65.97 Million | +21.18% |
| 2022 | $54.44 Million | +47.06% |
| 2021 | $37.02 Million | -66.93% |
| 2020 | $111.96 Million | -16.44% |
| 2019 | $134.00 Million | +6.19% |
| 2018 | $126.18 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 2nd, 2026 the market cap of Reviva Pharmaceuticals Holdings Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $6.02 Million USD |
| MoneyControl | $6.02 Million USD |
| MarketWatch | $6.02 Million USD |
| marketcap.company | $6.02 Million USD |
| Reuters | $6.02 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, s… Read more